News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Antonio Calles: Choose your path after MARIPOSA and COCOON trial presentations at ELCC25
Antonio Calles/X
Mar 28, 2025, 15:18

Antonio Calles: Choose your path after MARIPOSA and COCOON trial presentations at ELCC25

Antonio Calles, Head of the Lung Cancer Unit at Hospital Ruber Internacional, shared a post on X:

“So this is the situation in Paris tonight after high OS MARIPOSA trial and low toxicity within COCOON trial presentations.

Choose your path.”

More posts featuring Antonio Calles.

Antonio Calles cancer COCOON ELCC25 MARIPOSA OncoDaily Oncology
Special Coverage
Societies
Jun 4, 2025, 23:14
20 Posts Not to Miss from ASCO 2025
Career
Jun 4, 2025, 17:30
Fellowship and Short-Term Training Opportunities Now Open at POEM Training Centers - POEM Group
Celebrities
Jun 4, 2025, 17:16
Jessie J Diagnosed with Early-Stage Breast Cancer: What Is the Prognosis?
Blog
Jun 4, 2025, 17:13
Katy Rezvani Has Been Appointed as AACR 2026 Program Committee Co-Chair and Elected to the Association of American Physicians
Blog
Jun 4, 2025, 17:07
Teresa Amaral: The Fantastic Faculty of The ASCO and ESMO Session at ASCO25 Congress
Blog
Jun 4, 2025, 17:02
Jennifer Buell Highlights Strategic Partnership Between Agenus and Zydus
Blog
Jun 4, 2025, 16:52
Olubukola Ayodele: I Leave ASCO25 Feeling Recharged Not Just By Data But By Direction
Insight
Jun 4, 2025, 16:33
Paolo Tarantino on Sara Tolaney’s Leadership and Mentorship at ASCO 2025
Blog
Jun 4, 2025, 16:33
Maryam Lustberg: Grateful For My MASCC Family
Insight
Jun 4, 2025, 16:30
Jasmine Kamboj Celebrated ASCO Advocacy Award with Team Minnesota at ASCO 2025
Blog
Jun 4, 2025, 16:27
Hadieh Eslampanah: Happy International Cancer Survivors Day 2025 - New Life and New Beginning
Oncolibrary
Jun 4, 2025, 16:20
IMMUNOSARC II Study Results: Sunitinib Plus Nivolumab Shows Promising Activity in Advanced Extraskeletal Myxoid Chondrosarcoma (EMC)